Warning over off-label use

TGA cautions health practitioners about the off-label use of SGLT2 inhibitors, after reports associated with diabetic ketoacidosis The TGA is reminding health professionals about the risk of diabetic ketoacidosis with the off-label use of sodium glucose co-transporter 2 (SGLT2) inhibitors. While the medicines are approved for use in patients with type 2 diabetes mellitus (T2DM)

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Finding meaning and purpose
Next Say ‘yes’ to Wesfarmers, urges API